Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of costunolide in preparation of anti-hepatic fibrosis drugs

A technology of anti-hepatic fibrosis and woody lactone, which is applied in the field of medicine, can solve the problems of the decrease of new infection rate and the increase of the number of patients with liver fibrosis, etc., achieve the reduction of collagen deposition, enrich the variety, and improve the pathological structure of the liver Effect

Inactive Publication Date: 2018-10-12
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the new infection rate of hepatitis B virus has decreased significantly after the widespread use of preventive vaccines against hepatitis B virus, chronic hepatitis B is still an important factor causing the increase in the number of patients with liver fibrosis in my country due to the large base of hepatitis B patients in my country

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of costunolide in preparation of anti-hepatic fibrosis drugs
  • Application of costunolide in preparation of anti-hepatic fibrosis drugs
  • Application of costunolide in preparation of anti-hepatic fibrosis drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Inhibition of TGFβ1-induced expression of major markers of hepatic fibrosis in LX-2 cells at mRNA and protein levels

[0030] 1.1TGFβ1 induces LX-2 cells and woody lactone administration treatment: LX-2 in DMEM containing 10% (volume) fetal bovine serum, 1% (volume) penicillin-streptomycin mixed solution, High Glucose, GlutaMAX TM (Gibco 10566016) medium, 37°C, 5% CO 2 cultivated under conditions. Follow 1 x 10 per well 5 Each cell is laid on a 6-well plate, and after 24 hours of culture, use a vacuum pump to remove the original medium in the 6-well plate and add 2 ml / well of DMEM medium without 10% fetal bovine serum. After 24 hours of starvation culture, add TGF-β1 (2ng / ml) induction, and coynelides of different concentration gradients were added at the same time, and the concentrations were 5 μmmol / L and 10 μmmol / L respectively. β1 induction but treated with coylidene), TGF-β1 induction group (only TGF-β1 induction) and TGF-β1 induction administration group (both...

Embodiment 2

[0036] Effects of creolide on BDL-induced liver fibrosis in rats

[0037] 1. Preparation of liver fibrosis model induced by common bile duct ligation in SD rats

[0038] Select 24 male SD rats with a body weight of 180-220 g. The SD rats were purchased from Weitong Lihua Experimental Animal Technology Co., Ltd. in SPF packaging. SD male rats were randomly divided into sham operation group, model group, and cressin lactone administration group, with 8 rats in each group. After fasting without food and water for 12 hours before the animal experiment, the animals were anesthetized with isoflurane for surgery. Among them, the model group and the treatment group underwent common bile duct ligation (BDL). In the aseptic operating table, a midline incision was made in the upper abdomen, the liver margin was elevated, the duodenum was opened, and the common bile duct was separated by 2-3 cm. Two 000 surgical sutures were ligated at the place near the duodenum and near the porta hepa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of costunolide in preparation of anti-hepatic fibrosis drugs and belongs to the technical field of medicines. The anti-hepatic fibrosis drugs are prepared through the costunolide, the usage of the costunolide is increased, and meanwhile the kind of the anti-hepatic fibrosis drugs is enriched. According to the record of the embodiment, the costunolide can restrainexpression of hepatic fibrosis main markers in TGF-beta1 induced LX-2 cells on mRNA and protein levels and can restrain the level of BDL induced hepatic fibrosis rat serum ALT / AST / ALP and expressionof hepatic tissue fibrosis markers on the mRNA and protein levels, and accordingly BDL induced rat hepatic fibrosis is restrained; and meanwhile, through the costunolide, the BDL induced rat hepatic pathologic structure can be further improved, and the collagen deposition situation in the BDL rat hepatic tissue is obviously relieved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of woody lactone in the preparation of anti-hepatic fibrosis drugs. Background technique [0002] Liver fibrosis is an inevitable stage in the development of chronic liver diseases caused by various etiologies to liver cirrhosis, and it is also the body's repair and compensation response to various liver injuries, mainly manifested in the excessive synthesis of extracellular matrix (ECM) that constitutes scar tissue And the imbalance of ECM synthesis and degradation leads to its excessive deposition in the liver, which seriously damages the normal structure of the liver. If effective treatment is not given in time, liver cells will continue to be damaged, resulting in liver function decline accompanied by intrahepatic connective tissue formation and portal hypertension, which will eventually become the key pathological basis for primary liver cancer. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P1/16
CPCA61K31/365A61P1/16
Inventor 何红伟邵荣光葛茂旭张娜牛伟晓鲍云洋张镱萱赵午莉刘虹
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com